Current Partners

Currently Developing
BBI-4000
(sofpironium bromide) For Hyperhidrosis in Japan
Exclusive License - Mar. 2015
Currently Developing
BBI-3000 
(novel topical retinoid)
For Acne in N.America
Exclusive License - June 2014
Leading Skincare Company in S. Korea
&
Strategic Investor
Collaboration - Feb. 2013
Kaken Pharmaceutical Co., Ltd.

Currently Developing BBI-4000 (novel 'soft-anticholinergic') For Hyperhidrosis in Japan

Kaken (Tokyo Stock Exchange: 4521) is a Japanese specialty pharmaceutical company with a strong presence in the market of dermatology (antifungals) and orthopedics. The company’s primary areas of R&D focus include inflammation, immunology (dermatitis, rheumatoid arthritis and osteoarthritis), pain and antifungals. http://www.kaken.co.jp/english/index_notice.html

Merz North America

Currently Developing BBI-3000 (novel topical retinoid) For Acne in N.America

Merz North America is a specialty healthcare company that develops and commercializes innovative, high-quality treatment solutions in aesthetics, dermatology and neurosciences in the U.S. and Canada. Our ambition is to become the most admired, trusted and innovative aesthetics and neurotoxin company. By developing products that improve patients’ health and help them to live better, feel better and look better, we will continue to make significant contributions to the well-being of individuals around the world. Founded in 1908, Merz Pharma Group is a privately-owned company headquartered in Frankfurt, Germany. www.merzusa.com

AMOREPACIFIC GROUP

Leading Skincare Company in S. Korea & Strategic Investor

AMOREPACIFIC, based in Seoul, South Korea, is one of the leading cosmetic and aesthetics companies in Asia, with annual turnover of approximately $3 billion. AMOREPACIFIC Ventures, the corporate venture fund of AMOREPACIFIC, focuses on innovative technologies in beauty and aesthetic area. www.amorepacific.com